Very interesting paper about #complementbiology activation that drives antibody-mediated transfusion-related acute lung injury via macrophage trafficking and formation of NETs

ashpublications.org/blood/article-…

We greatly appreciate all who have so generously supported international #atypicalHUS advocacy through donations to aHUS Alliance Global Action! Learn more at bit.ly/DONATEaHUSglob…
Thanks to those honoring Aline’s birthday by supporting #aHUS global efforts. #RareDisease

spectrum of thrombotic microangiopathy related to monoclonal gammopathy | Clinical Kidney Journal | Oxford Academic academic.oup.com/ckj/advance-ar…

Update on C3 Glomerulopathy: A Complement-Mediated Disease ca. 2020 from Karger Publishers #Nephpearls

👉🏼 pubmed.ncbi.nlm.nih.gov/32369815/

Excellent review on present & future Complement inhibitors for kidney disease!! 💥 Columbia Nephrology Columbia Glomerular Center
We will talk about some of them in the upcoming: Update on complement and kidney. Free inscriptions: aulaclinic.com/cursos/view.ph… Hospital Clínic

ANCA-associated vasculitis (AAV) belongs to a group of small vessel systemic vasculitides characterized by granulomatous and neutrophilic inflammation of various tissues. This Review describes the evolution of treatment of AAV bit.ly/KID0289

Hypocomplementemia and complement co-deposition with monoclonal immunoglobulins in glomeruli are not rare in PGNMID. In this study, the complement system was found to be overactivated in PGNMID, & urinary complements correlated with disease severity bit.ly/CJASN0295

📖 This weekend don't miss our KIReports #ISNFridaySelection : Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy kireports.org/article/S2468-…

To raise #aHUS awareness at FDA last September a group of patients and carers hosted a listening session. And here there is a summary of what they said. aHUS Alliance Action ahusallianceaction.org/ahus-patients-…

“ #Eculizumab first” in the management of post- #transplant thrombotic microangiopathy ow.ly/svO550QpvR5 @kiREPORTS #openaccess #TMA

It's here! U.S. FDA held a Listening Session with atypical HUS patients & #aHUS advocates just prior to aHUS Awareness Day 2023 #aHUS 24Sept. ahusallianceaction.org/ahus-patients-… Details with direct link to the #FDA report.

Discover our range of solutions and stay on the forefront of C3 research. We have collected C3 detection methods, tools, applications, and products. Find out more:

hycultbiotech.com/complement-c3-…

That #aHUS transplant treatment question, prophylactic or rescue therapy, is down to individual circumstances and avoidance of doing harm. aHUS Alliance Action ahusallianceaction.org/transplant-ahu…

You need a reliable measurement of many #complementbiology biomarkers at the same time?
Read our new paper about the multiplex assay for complement biomarkers in plasma!
Congratulations Marie-Sophie Meuleman Anna Duval MA Dragon-Durey and team! Happy to take part
sciencedirect.com/science/articl…

Our series continues, a focus on the 15 questions #aHUS patients want to know more about: ahusallianceaction.org/transplant-ahu… Atypical HUS & #transplant Outcomes. #complement

Fully agree with Simon J. Clark!

To extend complement inhibitors 💊 from rare to common diseases, patient stratification will be key!

#complementbiology biomarkers for this include:
- 🧬 variants
- 🩸 levels & other bodily fluids e.g.🚽
- 🔬 tissue deposition
- ☢️ Molecular imaging

In 2024, about 4000 people will newly onset with the primary form of the #raredisease atypical HUS. ahusallianceaction.org/a-new-year-and…
About 1200 of of new #aHUS patients will be from China or India, an estimated 400 in the UK or EU, and an est 150+ in the USA. #TMA #cm_TMA #complement

Recommendations for Individualised Management of #aHUS in Adults ncbi.nlm.nih.gov/pmc/articles/P… Conclusion: 'advocate early treatment, maintenance for at least 6–12 months and treatment interruption guided by #genetic background, trigger factors, risk of relapse and evolution.'

Thrombotic microangiopathy - great visual abstract underscores why it’s vital to expand #MedEd & to learn more about #complement & secondary #TMA . Sobering data, to include atypical HUS findings #aHUS

IgA nephropathy is the most common primary GN worldwide, with dominant deposition of IgA and co-deposits of complement component 3 (C3). This study found that in Chinese patients with IgA nephropathy, variant rs6677604 was linked to mesangial C3 deposition bit.ly/CJASN0290